New version of the list of drugs excluded from RDTL funding on the Ministry of Health's Public Information Bulletin
An October update to the notice on drugs not covered by RDTL funding has appeared on the health ministry's Public Information Bulletin. The full list is in the PDF file attached to the page.

Roberto Sorin · Unsplash License
- 0views
- 0likes and saves
- 0skips
What has been published
The Ministry of Health has posted a new version of the announcement regarding non-reimbursed drugs under the RDTL in the Public Information Bulletin (BIP). According to the document's metadata, the first publication occurred on October 13, 2026, at 10:17 AM, and Joanna Sędek is responsible for its preparation (Announcement regarding the list of non-reimbursed drugs under RDTL – Ministry of Health).
Where to find the list of drugs
The BIP page does not provide the names of the preparations or the scope of changes in the content of the announcement. All data is included in the attached PDF file, the name of which indicates an update from October 2026. The editorial team did not have access to this document, so it cannot specify which items have been added, removed, or modified.
Other GIF announcements unrelated to RDTL
The archive of the Chief Pharmaceutical Inspectorate contains separate announcements that do not pertain to the RDTL program. The Inspectorate has informed, among other things, about the product Monover from August 22, 2024 (Announcement of the Chief Pharmaceutical Inspector dated August 22, 2024 – Chief Pharmaceutical Inspectorate), the rules for dispensing Pyralgina MAX from August 6, 2025 (Announcement of the Chief Pharmaceutical Inspector dated August 6, 2025 – Chief Pharmaceutical Inspectorate), the preparation of prescription drugs in pharmacies from raw materials other than fiber hemp from February 4, 2026 (Announcement of the Chief Pharmaceutical Inspector dated February 4, 2026 – Chief Pharmaceutical Inspectorate), the counterfeiting of Octenisept from February 20, 2026 (Announcement of the Chief Pharmaceutical Inspector dated February 20, 2026 – Chief Pharmaceutical Inspectorate), and the obligation to comply with the rules of mail-order sale of drugs from March 12, 2026 (Announcement of the Chief Pharmaceutical Inspector dated March 12, 2026 – Chief Pharmaceutical Inspectorate).
What to do to check the status of a drug
Patients and doctors who want to determine the current status of a specific preparation in the RDTL program should download the PDF file from the Public Information Bulletin of the Ministry of Health. Only in this document is there a complete list of items covered by the October update.
Sources
- [1]Komunikat w sprawie wykazu leków niefinansowanych w ramach RDTL· Ministerstwo Zdrowia
- [2]Komunikat Głównego Inspektora Farmaceutycznego z dnia 12 marca 2026 r.· Główny Inspektorat Farmaceutyczny
- [3]Komunikat Głównego Inspektora Farmaceutycznego z dnia 20 lutego 2026 r.· Główny Inspektorat Farmaceutyczny
- [4]Komunikat Głównego Inspektora Farmaceutycznego z dnia 4 lutego 2026 r.· Główny Inspektorat Farmaceutyczny
- [5]Komunikat Głównego Inspektora Farmaceutycznego z dnia 6 sierpnia 2025 r.· Główny Inspektorat Farmaceutyczny
- [6]Komunikat Głównego Inspektora Farmaceutycznego z dnia 22 sierpnia 2024 r.· Główny Inspektorat Farmaceutyczny
Discussion0
- No comments from this perspective yet. Be the first.